{"nctId":"NCT00400725","briefTitle":"Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis","startDateStruct":{"date":"2006-09-29","type":"ACTUAL"},"conditions":["Scalp Psoriasis"],"count":288,"armGroups":[{"label":"Initial Phase:- Clobex® Shampoo","type":"EXPERIMENTAL","interventionNames":["Drug: Clobex® Shampoo"]},{"label":"Maintenance Phase: Clobex® Shampoo","type":"EXPERIMENTAL","interventionNames":["Drug: Clobex® Shampoo"]},{"label":"Maintenance Phase: Clobex® Vehicle Shampoo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Clobex® Vehicle Shampoo"]}],"interventions":[{"name":"Clobex® Shampoo","otherNames":["Clobetasol Propionate 0.05% [weight by weight (W/W)]"]},{"name":"Clobex® Vehicle Shampoo","otherNames":[]},{"name":"Clobex® Shampoo","otherNames":["Clobetasol Propionate 0.05% (W/W)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects aged 18 years or older.\n* Subjects with moderate to severe scalp psoriasis\n\nExclusion Criteria:\n\n* Subjects who needed systemic treatment for their body psoriasis\n* Subjects with a washout period for topical treatment(s) on the scalp less than:\n\n  * Corticosteroids 2 weeks\n  * All other anti-psoriasis medications 2 weeks\n* Subjects with a washout period for systemic treatment(s) less than:\n\n  * PUVA therapy 4 weeks\n  * Biological therapies 12 weeks\n  * Treatments other than biologicals with a possible efficacy on psoriasis 4 weeks\n  * Treatment known to worsen psoriasis 2 weeks","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Maintenance Phase: Time to First Relapse","description":"Time to first relapse was defined as the duration between baseline of maintenance phase and the visit where the relapse occurred. The first relapse was defined as the first time during the maintenance phase when participant presented with a GSS \\>2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":"6.5"},{"groupId":"OG001","value":"56.8","spread":"4.7"}]}]}]},{"type":"SECONDARY","title":"Initial Phase: Percentage of Participants With Global Severity Scores","description":"Global severity score was evaluated on a scale of 0-4 and it was categorized as; Clear (score 0); no clinical signs or symptoms detected (hyperpigmentation or residual red coloration might be present), very mild (score 1); only very slight signs or symptoms detected (e.g., very fine scaling or slight erythema), mild (score 2); slight signs or symptoms detected (e.g., mild erythema and scaling, eventually associated to some barely detectable plaque elevation), moderate (score 3); moderate or clearly detectable signs or symptoms (e.g., definite redness with obvious scaling on a plaque that was elevated above skin level), severe (score 4); severe signs or symptoms detected (e.g., intense redness, profuse shedding, definite plaque thickness was most often present) where 0 indicates best and 4 indicates worst. Percentage of participants with GSS was reported. Missing Clobex® shampoo data were imputed using last observation carried forward (LOCF).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Initial Phase: Percentage of Participants With Pruritus Scores","description":"Pruritus (itching sensation) score of were evaluated on a scale from 0 - 3 (0 = None \\[no itching\\], 1 = Mild \\[slight itching\\], not really bothersome), 2 = Moderate \\[definite itching that is somewhat bothersome; without loss of sleep\\], and 3 = severe \\[intense itching that has caused pronounced discomfort; night rest interrupted and excoriations of the skin from scratching may be present\\]) , where 0 indicates best and 3 indicates worst. Percentage of participants with pruritus score was reported. Missing Clobex® shampoo data were imputed using last observation carried forward (LOCF).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Initial Phase: Percentage of Participants With Individual Category of Scalp Psoriasis Individual Signs (Erythema, Scaling and Plaque Thickening) Scores","description":"Individual sign scores of erythema (abnormal redness of skin), scaling (scales attached to the scalp), plaque thickening (a thickening or elevation of a circumscribed lesion or plaque) were evaluated on a scale of 0-4; 0= none , 1= mild , 2=moderate , 3= severe, 4= very severe, where 0 indicates best and 4 indicates worst. Percentage of participants with individual signs (erythema, scaling, and plaque thickening) scores were reported. Missing Clobex® shampoo data were imputed using last observation carried forward (LOCF).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants Who Had First Relapse","description":"The first relapse was defined as the first time during the maintenance phase when participant presented with a GSS \\>2. Relapse was categorized into relapse or no relapse. Percentage of participants with relapse were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"64.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.8","spread":null},{"groupId":"OG001","value":"76.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.7","spread":null},{"groupId":"OG001","value":"84.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.9","spread":null},{"groupId":"OG001","value":"89.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"90.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.9","spread":null},{"groupId":"OG001","value":"91.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Scalp Psoriasis Pruritus Score at First Time of Relapse","description":"Pruritus (itching sensation) score of were evaluated on a scale from 0 - 3 (0 = None \\[no itching\\], 1 = Mild \\[slight itching, not really bothersome\\], 2 = Moderate \\[definite itching that is somewhat bothersome; without loss of sleep\\], and 3 = severe \\[intense itching that has caused pronounced discomfort; night rest interrupted and excoriations of the skin from scratching may be present\\]) , where 0 indicates best and 3 indicates worst. Percentage of participants with scalp psoriasis pruritus score at first relapse was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"7.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"26.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.5","spread":null},{"groupId":"OG001","value":"52.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"13.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Individual Category of Scalp Psoriasis Individual Signs (Erythema, Scaling and Plaque Thickening) Scores at First Time of Relapse","description":"The first relapse was defined as the first time during the maintenance phase when participant presented with a GSS \\>2. Individual sign scores of erythema were evaluated on a scale of 0-4 (0= none, 1= mild, 2=moderate, 3= severe, 4= very severe), where 0 indicates best and 4 indicates worst. Percentage of participants with individual signs (erythema, scaling and plaque thickening) scores were reported. There were no participants in scaling category with 0 score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"13.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.4","spread":null},{"groupId":"OG001","value":"54.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"30.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.4","spread":null},{"groupId":"OG001","value":"64.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","spread":null},{"groupId":"OG001","value":"29.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":null},{"groupId":"OG001","value":"14.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":null},{"groupId":"OG001","value":"67.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null},{"groupId":"OG001","value":"14.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Number of Relapses Experienced","description":"Number of relapses of participants were categorized as 0; zero relapse, 1; one relapse, 2; two relapse, 3; three relapse, 4; two consecutive relapses.\n\nPercentage of participants with total number of relapses experienced during maintenance period was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":null},{"groupId":"OG001","value":"8.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":null},{"groupId":"OG001","value":"22.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"25.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"18.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":null},{"groupId":"OG001","value":"26.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":288},"commonTop":["Nesopharyngitis","Upper Respiratory Tract Infection","Gastroenteritis","Influenza","Skin Burning Sensation"]}}}